Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
David Planchard(Université Paris-Saclay), Solange Peters(University Hospital of Lausanne), Egbert F. Smit(Dutch Cancer Society), Matthew D. Hellmann(AstraZeneca (United States)), Martin Reck(German Center for Lung Research), Sanjay Popat(Royal Marsden NHS Foundation Trust), Tony Mok(Chinese University of Hong Kong), Keith M. Kerr(University of Aberdeen), Silvia Novello(University of Turin), Paul E. Van Schil(Antwerp University Hospital), Corinne Faivre‐Finn(University of Manchester)
Cited by 2,296
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k